Anish Suri - 31 Mar 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
PRESIDENT AND CSO
Signature
/s/ Anish Suri by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
31 Mar 2022
Net transactions value
-$34,492
Form type
4
Filing time
04 Apr 2022, 17:31:40 UTC
Previous filing
29 Mar 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise +16,668 +18% 110,706 31 Mar 2022 Direct F1
transaction CUE Common Stock Tax liability $34,492 -7,068 -6.4% $4.88 103,638 31 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Restricted Stock Units Options Exercise $0 -16,668 -100% $0.000000* 0 31 Mar 2022 Common Stock 16,668 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award
F2 Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3 The restricted stock units vest in three equal annual installments beginning on March 31, 2020.